AcelRx Pharmaceuticals has received a US patent which provides intellectual property protection for sufentanil NanoTab based products through late 2030.
The patent entitled, Small-Volume Oral Transmucosal Dosage Forms, describes a method of treating pain by administering a small-volume solid tablet containing sufentanil by adhering to the oral mucosa.
AcelRx president and CEO Richard King said, "We remain focused on continued expansion of our patent portfolio as we establish the safety and efficacy profile of our ARX-01 Sufentanil NanoTab PCA System, with first data from our Phase 3 program for ARX-01 expected later this year."
The patent covers AcelRx's NanoTab technology for delivering sufentanil with claims to elements of a method for treating pain by administering a small volume (<15mcl) substantially homogenous solid tablet containing the active ingredient sufentanil to the oral mucosa of a subject at the same time generating a minimal saliva response and delivering the majority of the drug through the transmucosal route resulting in consistent pharmacokinetics.
